Species | Target name | Source | Bibliographic reference |
---|---|---|---|
Candida albicans | beta-1,3-glucan synthase similar to S. cerevisiae GSC2 (YGR032W) and FKS1 (YLR342W) beta-1,3-glucan synthase | Starlite/ChEMBL | No references |
Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Toxoplasma gondii | 1,3-beta-glucan synthase component protein | 0.0512 | 0.4428 | 0.4428 |
Toxoplasma gondii | methionine aminopeptidase | 0.076 | 0.7688 | 0.7688 |
Trypanosoma cruzi | metallo- peptidase, Clan MG, Family M24 | 0.0936 | 1 | 1 |
Schistosoma mansoni | methionyl aminopeptidase 1 (M24 family) | 0.076 | 0.7688 | 1 |
Mycobacterium leprae | PROBABLE METHIONINE AMINOPEPTIDASE MAPA (MAP) (PEPTIDASE M) (MetAP) | 0.076 | 0.7688 | 0.5 |
Toxoplasma gondii | methionine aminopeptidase | 0.0936 | 1 | 1 |
Mycobacterium tuberculosis | Methionine aminopeptidase MapA (map) (peptidase M) (MetAP) | 0.076 | 0.7688 | 0.5 |
Mycobacterium leprae | PROBABLE METHIONINE AMINOPEPTIDASE MAPB (MAP) (PEPTIDASE M) | 0.076 | 0.7688 | 0.5 |
Echinococcus multilocularis | methionyl aminopeptidase 1 (M24 family) | 0.0936 | 1 | 1 |
Plasmodium falciparum | methionine aminopeptidase 1a, putative | 0.076 | 0.7688 | 0.7688 |
Plasmodium vivax | methionine aminopeptidase 1a, putative | 0.076 | 0.7688 | 0.7688 |
Toxoplasma gondii | methionine aminopeptidase, type i, putative | 0.076 | 0.7688 | 0.7688 |
Mycobacterium tuberculosis | Methionine aminopeptidase MapB (map) (peptidase M) | 0.076 | 0.7688 | 0.5 |
Leishmania major | methionine aminopeptidase, putative,metallo-peptidase, Clan MG, Family M24 | 0.0936 | 1 | 1 |
Chlamydia trachomatis | methionine aminopeptidase | 0.076 | 0.7688 | 0.5 |
Loa Loa (eye worm) | methionine aminopeptidase type I | 0.0936 | 1 | 1 |
Trypanosoma cruzi | metallo- peptidase, Clan MG, Family M24 | 0.0936 | 1 | 1 |
Plasmodium vivax | methionine aminopeptidase 1b, putative | 0.0936 | 1 | 1 |
Echinococcus multilocularis | tm gpcr rhodopsin gpcr rhodopsin superfamily | 0.0517 | 0.4496 | 0.3747 |
Trypanosoma brucei | methionine aminopeptidase, type I, putative | 0.0936 | 1 | 1 |
Echinococcus granulosus | tm gpcr rhodopsin | 0.0517 | 0.4496 | 0.3747 |
Wolbachia endosymbiont of Brugia malayi | methionine aminopeptidase | 0.076 | 0.7688 | 0.5 |
Trypanosoma brucei | methionine aminopeptidase, putative | 0.0936 | 1 | 1 |
Mycobacterium ulcerans | methionine aminopeptidase MapB | 0.076 | 0.7688 | 0.5 |
Mycobacterium ulcerans | methionine aminopeptidase | 0.076 | 0.7688 | 0.5 |
Treponema pallidum | methionine aminopeptidase (map) | 0.076 | 0.7688 | 0.5 |
Echinococcus multilocularis | methionyl aminopeptidase 1 (M24 family) | 0.076 | 0.7688 | 0.7374 |
Plasmodium falciparum | methionine aminopeptidase 1b, putative | 0.0936 | 1 | 1 |
Trypanosoma brucei | metallo- peptidase, Clan MG, Family M24 | 0.0936 | 1 | 1 |
Echinococcus granulosus | methionyl aminopeptidase 1 M24 family | 0.0936 | 1 | 1 |
Schistosoma mansoni | methionyl aminopeptidase 1 (M24 family) | 0.076 | 0.7688 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
ED99.9 (functional) | > 6 mg kg-1 | In vivo anti-Candida activity was determined in a mouse model of disseminated candidiasis (TOKA). | ChEMBL. | No reference |
IC50 (binding) | = 0.07 uM | Tested for inhibition of Beta-1,3-glucan synthase using a crude membrane of Candida albicans (MY 1208). | ChEMBL. | No reference |
IC50 (binding) | = 0.07 uM | Tested for inhibition of Beta-1,3-glucan synthase using a crude membrane of Candida albicans (MY 1208). | ChEMBL. | No reference |
MFC (functional) | = 0.25 ug ml-1 | In vitro Fungicidal activity (MFC) of the compound was tested against Candida albicans (MY 1055). | ChEMBL. | No reference |
MFC (functional) | = 0.25 ug ml-1 | In vitro Fungicidal activity (MFC) of the compound was tested against Candida albicans (MY 1055). | ChEMBL. | No reference |
MFC (functional) | = 2 ug ml-1 | In vitro Fungicidal activity (MFC) of the compound was tested against C. parapsilosis (MY 1010). | ChEMBL. | No reference |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.